Welcome to our dedicated page for Scilex Holding Company SEC filings (Ticker: SCLXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scilex Holding Company SEC filings page for the warrant symbol SCLXW provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Scilex’s common stock (SCLX) and its warrants to purchase common stock at an exercise price of $402.50 per share (SCLXW) are listed on The Nasdaq Stock Market LLC, and the company identifies itself as an emerging growth company in its reports.
Through forms such as Form 10-K, Form 10-Q, and Form S-1, Scilex describes its business of acquiring, developing, and commercializing non-opioid pain management products, including commercial products ZTlido ae, ELYXYB ae, and Gloperba ae, and product candidates SP-102, SP-103, and SP-104. The registration statement on Form S-1 specifically addresses aspects of the company’s warrants and related securities offerings.
Current reports on Form 8-K give detail on material events that may be relevant to SCLXW holders, such as warrant exchange agreements, new warrant issuances, equity lines of credit, and options to repurchase previously issued warrants. For example, Scilex has reported a Common Stock Purchase Agreement with an institutional investor, Warrant Exchange Agreements that modify existing warrant terms, and an option agreement with Oramed Pharmaceuticals Inc. to repurchase penny warrants. Other 8-K filings discuss Semnur Pharmaceuticals, Inc.’s merger agreement with Denali Capital Acquisition Corp. and changes in executive leadership.
These filings also disclose Scilex’s collaborations and licensing arrangements, including a worldwide exclusive license from Datavault AI Inc. for AI-driven tokenization technology in biotech and biopharma, and strategic investments in Datavault AI. Such agreements can influence Scilex’s long-term business model and potential revenue sources, and are documented in detail in the underlying exhibits and narrative sections.
On Stock Titan, investors can use AI-powered tools to review Scilex’s 10-K annual reports, 10-Q quarterly reports, S-1 registration statements, and 8-K current reports. AI-generated summaries help explain complex capital structure terms for SCLXW, highlight key risk factors and business descriptions, and surface notable items such as warrant terms, exchange ratios, and major financing arrangements, while real-time updates ensure new EDGAR filings are reflected promptly.
Scilex Holding Company reported a larger quarterly loss while remaining in a significant deficit position. For the three months ended March 31, 2026, net revenue was $8.6M, up from $5.0M a year earlier, but operating expenses of $40.8M drove a loss from operations of $32.2M.
After sizable fair value movements on derivatives, digital assets and equity investments, Scilex recorded a net loss attributable to common stockholders of $43.3M versus $26.1M in 2025. Cash and cash equivalents were $3.4M, with total assets of $293.6M and total liabilities of $547.7M, resulting in stockholders’ deficit of $249.2M. Management disclosed negative working capital of $459.8M and substantial doubt about the company’s ability to continue as a going concern, noting dependence on future financings and growth in sales of ZTlido, ELYXYB and GLOPERBA. The quarter also reflected a $65.3M balance of digital assets (Bitcoin) and an equity-method Datavault investment of $79.1M, with large unrealized and realized valuation swings affecting results.
Scilex Holding Company reported a larger quarterly loss while remaining in a significant deficit position. For the three months ended March 31, 2026, net revenue was $8.6M, up from $5.0M a year earlier, but operating expenses of $40.8M drove a loss from operations of $32.2M.
After sizable fair value movements on derivatives, digital assets and equity investments, Scilex recorded a net loss attributable to common stockholders of $43.3M versus $26.1M in 2025. Cash and cash equivalents were $3.4M, with total assets of $293.6M and total liabilities of $547.7M, resulting in stockholders’ deficit of $249.2M. Management disclosed negative working capital of $459.8M and substantial doubt about the company’s ability to continue as a going concern, noting dependence on future financings and growth in sales of ZTlido, ELYXYB and GLOPERBA. The quarter also reflected a $65.3M balance of digital assets (Bitcoin) and an equity-method Datavault investment of $79.1M, with large unrealized and realized valuation swings affecting results.
Scilex Holding Company notified the SEC that it cannot file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 by the prescribed due date of May 15, 2026. The company says it needs additional time to finalize financial statements, including the consolidation of Vivasor Holding Company, and expects to file the Form 10-Q on or before May 20, 2026 (the fifth calendar day following the prescribed due date). The notification was signed by CFO Stephen Ma and cites Rule 12b-25 relief for a short extension to complete the filing.
Scilex Holding Company notified the SEC that it cannot file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 by the prescribed due date of May 15, 2026. The company says it needs additional time to finalize financial statements, including the consolidation of Vivasor Holding Company, and expects to file the Form 10-Q on or before May 20, 2026 (the fifth calendar day following the prescribed due date). The notification was signed by CFO Stephen Ma and cites Rule 12b-25 relief for a short extension to complete the filing.
Scilex Holding Company is moving ahead with a previously declared special dividend of Dream Bowl Meme Coin I digital tokens to certain equity holders. Eligible record holders of common stock, specified warrants, Tranche B convertible notes, and Series A preferred stock as of April 30, 2026 will receive five Dream Bowl Tokens for each share of common stock held or underlying their securities.
The dividend is scheduled to begin paying on May 26, 2026, but the board may change the record or payment dates or revoke the dividend entirely. Holders must open a Datavault AI digital wallet and submit an Opt-In Agreement via the company’s dividend website to receive tokens. Scilex describes the Dream Bowl Token as a digital collectible with no equity, voting, or payment rights, initially valued at $0 per token as of May 8, 2026, and plans a future listing on the Biconomy cryptocurrency exchange.
Scilex Holding Company is moving ahead with a previously declared special dividend of Dream Bowl Meme Coin I digital tokens to certain equity holders. Eligible record holders of common stock, specified warrants, Tranche B convertible notes, and Series A preferred stock as of April 30, 2026 will receive five Dream Bowl Tokens for each share of common stock held or underlying their securities.
The dividend is scheduled to begin paying on May 26, 2026, but the board may change the record or payment dates or revoke the dividend entirely. Holders must open a Datavault AI digital wallet and submit an Opt-In Agreement via the company’s dividend website to receive tokens. Scilex describes the Dream Bowl Token as a digital collectible with no equity, voting, or payment rights, initially valued at $0 per token as of May 8, 2026, and plans a future listing on the Biconomy cryptocurrency exchange.
Scilex Holding Company disclosed that indirect subsidiary ACEA Therapeutics agreed to sell 100% of ACEA Pharma to Phoenix Asia Holdings in a stock acquisition valued at $1,000,000,000.
ACEA Therapeutics will receive 100,000,000 newly issued Phoenix shares at $10.00 per share and is expected to own about 82% of Phoenix after closing. The transaction, unanimously approved by the boards, is expected to close by the end of the second quarter of 2026, subject to Hart-Scott-Rodino antitrust clearance, Nasdaq-related approvals and other customary conditions.
Scilex Holding Company disclosed that indirect subsidiary ACEA Therapeutics agreed to sell 100% of ACEA Pharma to Phoenix Asia Holdings in a stock acquisition valued at $1,000,000,000.
ACEA Therapeutics will receive 100,000,000 newly issued Phoenix shares at $10.00 per share and is expected to own about 82% of Phoenix after closing. The transaction, unanimously approved by the boards, is expected to close by the end of the second quarter of 2026, subject to Hart-Scott-Rodino antitrust clearance, Nasdaq-related approvals and other customary conditions.
Scilex Holding Company entered into a binding term sheet with Datavault AI Inc. for a proposed cash contribution and revenue participation arrangement tied to Datavault’s planned Quantum-Ready Edge Network in about 100 U.S. cities.
Scilex expects to make an upfront cash contribution of $120,000,000, paid in multiple closings with the final closing no later than December 31, 2026. In return, Datavault would pay Scilex 30% of Network Revenues until payments total $250,000,000, then 15% until combined payments reach $1,200,000,000, and 5% of Network Revenues for the remaining lifetime of the GPUs purchased with the upfront funds. The arrangement remains subject to negotiation and execution of definitive agreements, satisfaction of customary closing conditions, and achievement of specified operational and financial milestones, and may ultimately not be completed.
Scilex Holding Company entered into a binding term sheet with Datavault AI Inc. for a proposed cash contribution and revenue participation arrangement tied to Datavault’s planned Quantum-Ready Edge Network in about 100 U.S. cities.
Scilex expects to make an upfront cash contribution of $120,000,000, paid in multiple closings with the final closing no later than December 31, 2026. In return, Datavault would pay Scilex 30% of Network Revenues until payments total $250,000,000, then 15% until combined payments reach $1,200,000,000, and 5% of Network Revenues for the remaining lifetime of the GPUs purchased with the upfront funds. The arrangement remains subject to negotiation and execution of definitive agreements, satisfaction of customary closing conditions, and achievement of specified operational and financial milestones, and may ultimately not be completed.
Scilex Holding Co director and CFO Stephen Hoi Ma reported an open-market purchase of 650,000 warrants. Each warrant was bought at $0.1538 and gives the right to buy one share of common stock at an exercise price of $1.20 per share.
The warrants were acquired on April 17, 2026 and are scheduled to expire on June 18, 2029. Following this transaction, Ma holds 650,000 warrants, each exercisable for one share of Scilex common stock.
Scilex Holding Co director and CFO Stephen Hoi Ma reported an open-market purchase of 650,000 warrants. Each warrant was bought at $0.1538 and gives the right to buy one share of common stock at an exercise price of $1.20 per share.
The warrants were acquired on April 17, 2026 and are scheduled to expire on June 18, 2029. Following this transaction, Ma holds 650,000 warrants, each exercisable for one share of Scilex common stock.
Scilex Holding Co executive Henry Ji reported mixed warrant trades. On April 16, 2026, he made an open-market purchase of 3,250,000 warrants at $0.1538 per warrant, each exercisable at $1.20 for common stock. On April 17, 2026, he sold 650,000 warrants at the same price, leaving 2,600,000 warrants held directly, expiring on June 18, 2029.
Scilex Holding Co executive Henry Ji reported mixed warrant trades. On April 16, 2026, he made an open-market purchase of 3,250,000 warrants at $0.1538 per warrant, each exercisable at $1.20 for common stock. On April 17, 2026, he sold 650,000 warrants at the same price, leaving 2,600,000 warrants held directly, expiring on June 18, 2029.
Scilex Holding Company filed a Form S-3 to register up to $500,000,000 of securities on a shelf. The shelf prospectus permits offers of common stock, preferred stock, debt securities, warrants, rights and units in one or more offerings. The document describes existing commercial products (ZTlido, ELYXYB, GLOPERBA), pipeline assets (SP-102, SP-103, SP-104), certain corporate history and governance provisions, and states proceeds are intended for working capital and general corporate purposes.
Scilex Holding Company filed a Form S-3 to register up to $500,000,000 of securities on a shelf. The shelf prospectus permits offers of common stock, preferred stock, debt securities, warrants, rights and units in one or more offerings. The document describes existing commercial products (ZTlido, ELYXYB, GLOPERBA), pipeline assets (SP-102, SP-103, SP-104), certain corporate history and governance provisions, and states proceeds are intended for working capital and general corporate purposes.